<DOC>
	<DOCNO>NCT00054275</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes necessary tumor cell growth . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining erlotinib docetaxel may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine erlotinib docetaxel treat patient stage IV recurrent breast cancer .</brief_summary>
	<brief_title>Erlotinib Plus Docetaxel Treating Patients With Stage IV Recurrent Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine antitumor effect erlotinib docetaxel , term objective response , stabilization disease , progression-free survival , patient stage IV recurrent breast cancer . - Determine time tumor progression patient treat regimen . - Compare time tumor progression patient achieve disease stabilization response treatment regimen continue receive erlotinib versus patient receive additional erlotinib . OUTLINE : Patients receive docetaxel IV 1 hour weekly 3 week oral erlotinib daily begin day 1 . Treatment repeat every 4 week minimum 6 course absence unacceptable toxicity disease progression . Patients achieve maximal tumor response stabilization disease 6 course may continue receive erlotinib alone disease progression . Patients follow survival . PROJECTED ACCRUAL : A total 30 patient accrue study within 12-14 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IV recurrent adenocarcinoma breast Measurable disease Disease recurrence must within 1 year receive prior adjuvant docetaxel Stable brain metastasis allow Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Male female Menopausal status Not specify Performance status ECOG ( Eastern Cooperative Oncology Group ) 02 OR Karnofsky 60100 % Life expectancy More 6 month Hematopoietic WBC ( White Blood Count ) least 3,000/mm^3 Platelet count least 100,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Hemoglobin least 8 g/dL Hepatic Bilirubin normal AST ( aspartate aminotransferase ) /ALT ( alanine aminotransferase ) great 2.5 time upper limit normal Renal Creatinine normal OR Creatinine clearance least 60 mL/min No clinically significant proteinuria No significant impairment renal function Cardiovascular No New York Heart Association class III IV heart disease No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia No inadequately control hypertension Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No prior severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 No malignancy within past 10 year except inactive nonmelanoma skin cancer , carcinoma situ cervix , carcinoma situ breast , bilateral breast cancer No ongoing active infection No peripheral neuropathy great grade 1 No concurrent uncontrolled medical condition would preclude study participation No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy Prior trastuzumab ( Herceptin ) allow Chemotherapy See Disease Characteristics No prior chemotherapy recurrent metastatic disease Prior adjuvant chemotherapy allow Endocrine therapy Prior hormonal therapy allow Radiotherapy Not specify Surgery Not specify Other No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>